CDD-2807 is a chemical compound which acts as a potent and selective inhibitor of serine/threonine-protein kinase 33 (STK33), with a IC50 of 9.2 nM. In animal studies it causes production of abnormal sperm with reduced motility, and it has been investigated as a potential male contraceptive drug.[1][2]

CDD-2807
Identifiers
  • (3-([1,1'-Biphenyl]-2-ylethynyl)-1H-indazol-5-yl)(2,6-diazaspiro[3.5]nonan-2-yl)methanone
Chemical and physical data
FormulaC29H26N4O
Molar mass446.554 g·mol−1
3D model (JSmol)
  • O=C(N1CC2(C1)CNCCC2)c1cc2c([NH]nc2C#Cc2ccccc2c2ccccc2)cc1
  • InChI=InChI=1S/C29H26N4O/c34-28(33-19-29(20-33)15-6-16-30-18-29)23-12-14-27-25(17-23)26(31-32-27)13-11-22-9-4-5-10-24(22)21-7-2-1-3-8-21/h1-5,7-10,12,14,17,30H,6,15-16,18-20H2,(H,31,32)
  • Key:YXMAOKMVGOSRPS-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ Holdaway J, Georg GI (May 2024). "An emerging target for male contraception". Science. 384 (6698): 849–850. Bibcode:2024Sci...384..849H. doi:10.1126/science.adp6432. PMID 38781397.
  2. ^ Ku AF, Sharma KL, Ta HM, Sutton CM, Bohren KM, Wang Y, et al. (May 2024). "Reversible male contraception by targeted inhibition of serine/threonine kinase 33". Science. 384 (6698): 885–890. Bibcode:2024Sci...384..885K. doi:10.1126/science.adl2688. PMID 38781365.